NEW YORK, Jan. 22, 2018 /PRNewswire/ -- Rowley Law
PLLC is investigating potential claims against Juno Therapeutics,
Inc. (NASDAQ: JUNO) and its board of directors for breach of
fiduciary duty concerning the proposed acquisition of the company
by Celgene Corporation. Stockholders will receive $87.00 for each share of Juno Therapeutics, Inc.
that they hold. The transaction is valued at approximately
$9 billion and is expected to close
in the first quarter of 2018.
If you are a stockholder of Juno Therapeutics, Inc. and are
interested in obtaining additional information regarding this
investigation, please visit us at:
http://www.rowleylawpllc.com/investigation/juno. You may
also contact Shane Rowley, Esq. at
Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at
info@rowleylawpllc.com, or by telephone at 914-400-1920 or
844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class
actions and derivative lawsuits in complex corporate litigation.
For more information about the firm and its attorneys, please visit
http://www.rowleylawpllc.com.
Attorney Advertising. Prior results do not guarantee a similar
outcome.
View original
content:http://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-juno-therapeutics-inc-300585948.html
SOURCE Rowley Law PLLC